AC Immune (ACIU) Stock Price, News & Analysis

Company Overview

AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical studies trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that is in Phase Ib/2a clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.

Key Stats

• Today's Range: $1.65 to $1.73
• 50-Day Range: $1.48 to $2.22
• 52-Week Range: $1.43 to $4.98
• Volume: 68,999 shs
• Average Volume: 167,587 shs
• Market Capitalization: $169.69 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Buy

AC Immune Stock Analysis - MarketRank™

AC Immune scored higher than 52% of companies evaluated by MarketBeat, and ranked 500th out of 918 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Buy

Consensus Rating

AC Immune has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

Amount of Analyst Coverage

AC Immune has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for AC Immune are expected to grow in the coming year, from ($0.62) to ($0.07) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of AC Immune is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of AC Immune is -3.67, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

AC Immune has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.25% of the float of AC Immune has been sold short.

Short Interest Ratio / Days to Cover

AC Immune has a short interest ratio ("days to cover") of 7.5.

Change versus previous month

Short interest in AC Immune has recently decreased by 4.83%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

AC Immune does not currently pay a dividend.

Dividend Growth

AC Immune does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

2.25% of the float of AC Immune has been sold short.

Short Interest Ratio / Days to Cover

AC Immune has a short interest ratio ("days to cover") of 7.5.

Change versus previous month

Short interest in AC Immune has recently decreased by 4.83%, indicating that investor sentiment is improving.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: N/A

News Sentiment

AC Immune has a news sentiment score of 1.40. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.75 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for AC Immune this week, compared to 1 article on an average week.

MarketBeat Follows

Only 1 people have added AC Immune to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, AC Immune insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 4.60% of the stock of AC Immune is held by insiders.

Percentage Held by Institutions

51.36% of the stock of AC Immune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

ACIU Stock Analysis - Frequently Asked Questions

How have ACIU shares performed this year?

AC Immune's stock was trading at $2.70 at the beginning of the year. Since then, ACIU stock has decreased by 37.4% and is now trading at $1.69.
View the best growth stocks for 2025 here.

How were AC Immune's earnings last quarter?

AC Immune SA (NASDAQ:ACIU) announced its quarterly earnings data on Wednesday, April, 30th. The company reported ($0.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.22) by $0.01. The company had revenue of $1.12 million for the quarter, compared to the consensus estimate of $1.99 million.

When did AC Immune IPO?

AC Immune (ACIU) raised $55 million in an IPO on Friday, September 23rd 2016. The company issued 4,600,000 shares at a price of $11.00-$13.00 per share. Credit Suisse, Jefferies and Leerink Partners served as the underwriters for the IPO.

Who are AC Immune's major shareholders?

AC Immune's top institutional investors include BVF Inc. IL (19.74%), Acadian Asset Management LLC (0.37%), Handelsbanken Fonder AB (0.13%) and Banque Cantonale Vaudoise (0.03%).

How do I buy shares of AC Immune?

Shares of ACIU stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of AC Immune own?

Based on aggregate information from My MarketBeat watchlists, some other companies that AC Immune investors own include Meta Platforms (META), NVIDIA (NVDA), Corbus Pharmaceuticals (CRBP), Sorrento Therapeutics (SRNE), Tesla (TSLA), Advanced Micro Devices (AMD) and Canopy Growth (CGC).

Company Calendar

• Last Earnings: 4/30/2025
• Today: 5/25/2025
• Next Earnings (Estimated): 8/05/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:ACIU
• CIK: 1651625
• Web: www.acimmune.com
• Phone: (121) 345-9121
• Fax: 41-21-345-9120
• Employees: 140
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $12.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +491.7%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($0.58)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-60,410,000.00
• Net Margins: N/A
• Pretax Margin: -95.58%
• Return on Equity: -28.26%
• Return on Assets: -18.98%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.86
• Quick Ratio: 1.86

Sales & Book Value

• Annual Sales: $28.30 million
• Price / Sales: 6.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $2.12 per share
• Price / Book: 0.80

Miscellaneous

• Outstanding Shares: 100,410,000
• Free Float: 94,389,000
• Market Cap: $169.69 million
• Optionable: Optionable
• Beta: 1.62